Braintree Laboratories, a part of US-based Sebela Pharmaceuticals and a manufacturer of gastroenterology pharmaceutical products, announced on Wednesday positive topline results from two pivotal US Phase 3 clinical trials evaluating tegoprazan, a novel potassium-competitive acid blocker (P-CAB), in patients with gastroesophageal reflux disease (GERD).
The company says that across both the erosive esophagitis (EE) and non-erosive reflux disease (NERD) pivotal studies known as TRIUMpH, tegoprazan achieved significance in all primary and secondary endpoints tested. This included statistical superiority over a PPI (lansoprazole) in achieving complete oesophageal healing at weeks 2 and 8 across all grades of EE, including the significant cohort of patients with severe disease (LA Grades C & D). In the NERD trial, tegoprazan demonstrated complete symptom relief for both heartburn (overnight and heartburn free days) and regurgitation.
The maintenance phase of the EE study will complete in Q3 2025 with a New Drug Application inclusive of both the EE and NERD indications planned for filing with FDA in Q4 2025. Braintree says that it intends to submit results from the TRIUMpH Phase 3 studies to a high impact, peer reviewed journal, along with presentation of this data at a leading gastroenterology conference in the future.
A US-based Phase 1 pharmacodynamic study has demonstrated that tegoprazan can provide more rapid acid control (pH>4) within 45 minutes, with no food effect.
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
Nutshell Therapeutics' NTS071 p53 allosteric reactivator cleared for US clinical trial
Blue Earth Therapeutics initiates Phase 2 trial in metastatic castrate resistant prostate cancer
Armata Pharmaceuticals' AP-SA02 clinical trial receives additional US DoD funding
S&E bio's SNE-101 stroke therapy approved for clinical trial
TransCode Therapeutics reports progress in metastatic cancer trial